Erratum: Antimalarial drug discovery - approaches and progress towards new medicines (Nature Reviews Microbiology (2013) 11 (849-862) DOI: 10.1038/nrmicro3138);Antimalarial drug discovery-approaches and progress towards new medicines

Nature Reviews Microbiology

Volumn 11, Issue 12, 2013, Pages 849-862

  Flannery, Erika L ^a   Chatterjee, Arnab K ^b   Winzeler, Elizabeth A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b California Institute for Biomedical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOPYRIDINE DERIVATIVE; 21A092; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTEROLANE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE PLUS PROGUANIL; BCX 4945; CHLOROQUINE; COARSUCAM; DIHYDROARTEMISININ PLUS PIPERAQUINE; DSM 265; ELQ 300; FERROQUINE; GNF 156; GSK 1057714; KAE 609; KAF 156; MMV 390048; NATURAL PRODUCT; NEW DRUG; NITD 609; NPC 1161B; OZ 439; P 218; PLANT EXTRACT; PYRIMETHAMINE PLUS SULFADOXINE; RKA 182; TAFENOQUINE; TCMDC 139046; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL ACTIVITY; ARGEMONE MEXICANA; CHEMOPROPHYLAXIS; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG REFORMULATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENDEMIC DISEASE; ERADICATION THERAPY; HIGH THROUGHPUT SCREENING; HOST PARASITE INTERACTION; HUMAN; INSECTICIDE RESISTANCE; LIFE CYCLE; MALARIA; MALARIA CONTROL; NONHUMAN; PARASITE DEVELOPMENT; PARASITE TRANSMISSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; SCID MOUSE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TRAVEL; VECTOR CONTROL;

EID: 84887989421     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro.2017.88     Document Type: Erratum

References (134)

1. Singh, B. & Daneshvar, C. Human infections and detection of Plasmodium knowlesi. Clin. Microbiol. Rev. 26, 165-184 (2013).
2. World Health Organization. World Malaria Report 2012. [online] http://www.who.int/malaria/publications/world-malaria-report-2012/en/(WHO, 2012).
3. Murray, C. J. et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379, 413-431 (2012)
4. Beutler, E. The hemolytic effect of primaquine and related compounds: a review. Blood 14, 103-139 (1959).
5. Guerra, C. A. et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4, e774 (2010).
6. Tanner, M. & de Savigny, D. Malaria eradication back on the table. Bull. World Health Organiz. 86, 82 (2008). (Pubitemid 351213705)
7. Kappe, S. H., Vaughan, A. M., Boddey, J. A. & Cowman, A. F. That was then but this is now: malaria research in the time of an eradication agenda. Science 328, 862-866 (2010).
8. Alonso, P. et al. A research agenda for malaria eradication: drugs. PLoS Med. 8, e1000402 (2011).
9. Burrows, J. N., Hooft van Huijsduijnen, R., Mohrle, J. J., Oeuvray, C. & Wells, T. N. Designing the next generation of medicines for malaria control and eradication. Malar. J. 12, 187 (2013).
10. Peatey, C. L., Spicer, T. P., Hodder, P. S., Trenholme, K. R. & Gardiner, D. L. A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes. Mol. Biochem. Parasitol. 180, 127-131 (2011).
11. Dembele, L. et al. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS ONE 6, e18162 (2011)
12. Buchholz, K. et al. A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J. Infect. Dis. 203, 1445-1453 (2011).
13. Tanaka, T. Q. & Williamson, K. C. A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue. Mol. Biochem. Parasitol. 177, 160-163 (2011).
14. Lucantoni, L. & Avery, V. Whole-cell in vitro screening for gametocytocidal compounds. Future Med. Chem. 4, 2337-2360 (2012).
15. Derbyshire, E. R., Mota, M. M. & Clardy, J. The next opportunity in anti-malaria drug discovery: the liver stage. PLoS Pathog. 7, e1002178 (2011).
16. Swinney, D. C. & Anthony, J. How were new medicines discovered? Nature Rev. Drug Discov. 10, 507-519 (2011).
17. Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nature Rev. Drug Discov. 10, 188-195 (2011).
18. Gamo, F. J. et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010).
19. Guiguemde, W. A. et al. Chemical genetics of Plasmodium falciparum. Nature 465, 311-315 (2010).
20. Plouffe, D. et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci. USA 105, 9059-9064 (2008)
21. Smilkstein, M. Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. & Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48, 1803-1806 (2004). (Pubitemid 38544392)
22. Guiguemde, W. A. et al. Global phenotypic screening for antimalarials. Chem. Biol. 19, 116-129 (2012).
23. Yeung, B. K. et al. Spirotetrahydro ?-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J. Med. Chem. 53, 5155-5164 (2010).
24. Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010)
25. van Pelt-Koops, J. C. et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544-3548 (2012).
26. Spillman, N. J. et al. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13, 227-237 (2013).
27. Tse, M. T. Antimalarial drugs: speeding to a new lead. Nature Rev. Drug Discov. 9, 842 (2010).
28. Calderon, F. et al. An invitation to open innovation in malaria drug discovery: 47 quality starting points from the TCAMS. ACS Med. Chem. Lett. 2, 741-746 (2011).
29. Calderon, F. et al. A divergent SAR study allows optimization of a potent 5-HT2c inhibitor to a promising antimalarial scaffold. ACS Med. Chem. Lett. 3, 373-377 (2012).
30. Rueda, L. et al. Cyclopropyl carboxamides: A new oral antimalarial series derived from the Tres Cantos Anti-Malarial Set (TCAMS). ACS Med. Chem. Lett. 2, 840-844 (2011).
31. Sanz, L. M. et al. Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob. Agents Chemother. 55, 5740-5745 (2011).
32. Harris, C. J., Hill, R. D., Sheppard, D. W., Slater, M. J. & Stouten, P. F. The design and application of target-focused compound libraries. Comb. Chem. High Throughput Screen. 14, 521-531 (2011).
33. Duffy, S. & Avery, V. M. Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. Am. J. Trop. Med. Hyg. 86, 84-92 (2012).
34. Younis, Y. et al. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J. Med. Chem. 55, 3479-3487 (2012)
35. Eastman, R. T. et al. A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. Antimicrob. Agents Chemother. 57, 425-435 (2013).
36. Huang, W., Luo, M., Zhou, M. & Pan, X. Study on the treatment of Plasmodium cynomolgi infections of the macaque with ketotifen. Acta Pharmaceut. Sin. 22, 409 (1987).
37. Singh, N. & Puri, S. Inhibition of the development of the hepatic stages of Plasmodium yoelii nigeriensis by antihistaminic agents. Ann. Trop. Med. Parasitol. 93, 419 (1999).
38. Milner, E. et al. Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. Eur. J. Drug Metab. Pharmacokinet. 37, 17-22 (2012).
39. Mazier, D., Renia, L. & Snounou, G. A pre-emptive strike against malaria's stealthy hepatic forms. Nature Rev. Drug Discov. 8, 854-864 (2009).
40. Carraz, M.l. et al. A plant-derived morphinan as a novel lead compound active against malaria liver stages. PLoS Med. 3, e513 (2006).
41. Meister, S. et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372-1377 (2011)
42. Nagle, A. et al. Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J. Med. Chem. 55, 4244-4273 (2012).
43. Wu, T. et al. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J. Med. Chem. 54, 5116-5130 (2011).
44. Derbyshire, E. R., Prudencio, M., Mota, M. M. & Clardy, J. Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. Proc. Natl Acad. Sci. USA 109, 8511-8516 (2012).
45. da Cruz, F. P. et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J. Infect. Dis. 205, 1278-1286 (2012).
46. Yekutiel, P. III.The Global Malaria Eradication Campaign (ed. Klingberg, M. A.) 34-88 (Karger, 1980).
47. Schmidt, L. H., Fradkin, R., Vaughan, D. & Rasco, J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am. J. Trop. Med. Hyg. 26, 1116-1128 (1977). (Pubitemid 8260922)
48. Vale, N., Moreira, R. & Gomes, P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44, 937-953 (2009).
49. Chiang, T. Y., Lin, W. C., Kuo, M. C., Ji, D. D. & Fang, C. T. Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses. Clin. Microbiol. Infect. 18, E232-E234 (2012).
50. Bright, A. T. et al. Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. Emerg. Infect. Dis. 19, 802 (2013).
51. D'Alessandro, S. et al. A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. J. Antimicrob. Chemother. 68, 2048-2058 (2013).
52. Delves, M. J. et al. A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. Int. J. Parasitol. 42, 999-1006 (2012).
53. Blagborough, A. M. et al. Assessing transmission blockade in Plasmodium spp. Methods Mol. Biol. 923, 577-600 (2013).
54. Vennerstrom, J. L. et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430, 900-904 (2004) (Pubitemid 39119218)
55. Klonis, N. et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc. Natl Acad. Sci. USA 108, 11405-11410 (2011).
56. Olliaro, P. & Wells, T. N. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther. 85, 584-595 (2009).
57. Enserink, M. If artemisinin drugs fail, what's plan B? Science 328, 846 (2010).
58. Charman, S. A. et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl Acad. Sci. USA 108, 4400-4405 (2011).
59. Delves, M. et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 9, e1001169 (2012).
60. Moehrle, J. J. et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br. J. Clin. Pharmacol. 75, 524-537 (2013).
61. O'Neill, P. M. et al. Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew. Chem. Int. Ed. Engl. 49, 5693-5697 (2010).
62. Wang, X. et al. Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. J. Med. Chem. 56, 2547-2555 (2013).
63. Peters, W., Robinson, B. L. & Milhous, W. K. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann. Trop. Med. Parasitol. 87, 547-552 (1993). (Pubitemid 24029001)
64. Nanayakkara, N. P. et al. Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]- 6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinol ine succinate. Antimicrob. Agents Chemother. 52, 2130-2137 (2008). (Pubitemid 351758550)
65. Baird, J. K. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev. 22, 508-534 (2009).
66. Pybus, B. S. et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar. J. 11, 259 (2012).
67. Winter, R. et al. Optimization of endochin-like quinolones for antimalarial activity. Exp. Parasitol. 127, 545-551 (2011).
68. Nilsen, A. et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci. Transl. Med. 5, 177ra37 (2013).
69. Muregi, F. W. & Ishih, A. Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design. Drug Dev. Res. 71, 20-32 (2010).
70. Kelly, J. X. et al. Discovery of dual function acridones as a new antimalarial chemotype. Nature 459, 270-273 (2009).
71. Dubar, F. et al. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem. Biol. 6, 275-287 (2011).
72. Dubar, F., Khalife, J., Brocard, J., Dive, D. & Biot, C. Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action. Molecules 13, 2900-2907 (2008).
73. White, N. J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7, 549-558 (2007). (Pubitemid 47077715)
74. Fermini, B. & Fossa, A. A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev. Drug Discov. 2, 439-447 (2003). (Pubitemid 37361725)
75. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29-40 (2007) (Pubitemid 46020284)
76. Yuthavong, Y. et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc. Natl Acad. Sci. USA 109, 16823-16828 (2012)
77. Anthony, M. P., Burrows, J. N., Duparc, S., Moehrle, J. J. & Wells, T. N. The global pipeline of new medicines for the control and elimination of malaria. Malar. J. 11, 316 (2012).
78. Ittarat, I., Asawamahasakda, W. & Meshnick, S. R. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp. Parasitol. 79, 50-56 (1994). (Pubitemid 24270438)
79. Reyes, P. et al. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol. 5, 275-290 (1982).
80. Baldwin, J. et al. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 280, 21847-21853 (2005). (Pubitemid 40827835)
81. Gujjar, R. et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem. 52, 1864-1872 (2009).
82. Gujjar, R. et al. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J. Med. Chem. 54, 3935-3949 (2011).
83. Coteron, J. M. et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem. 54, 5540-5561 (2011).
84. Patel, V. et al. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 283, 35078-35085 (2008).
85. Booker, M. L. et al. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J. Biol. Chem. 285, 33054-33064 (2010).
86. Kortagere, S. et al. Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. J. Chem. Inf. Model. 50, 840-849 (2010).
87. Dharia, N. V. et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10, R21 (2009).
88. Hoepfner, D. et al. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 11, 654-663 (2012).
89. Istvan, E. S. et al. Validation of isoleucine utilization targets in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 108, 1627-1632 (2011).
90. Dong, C. K. et al. Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem. Biol. 18, 1602-1610 (2011).
91. Nam, T. G. et al. A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem. Biol. 6, 1214-1222 (2011).
92. Zhou, H., Sun, L., Yang, X.-L. & Schimmel, P. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature 494, 121-124 (2012).
93. Derbyshire, E. R., Mazitschek, R. & Clardy, J. Characterization of Plasmodium liver stage inhibition by halofuginone. ChemMedChem. 7, 844-849 (2012).
94. Crowther, G. J. et al. Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol. Biochem. Parasitol. 175, 21-29 (2011).
95. Wells, T. N. Natural products as starting points for future anti-malarial therapies: going back to our roots. Malar. J. 10, S3 (2011).
96. Mesia, K. et al. Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract. J. Ethnopharmacol. 131, 10-16 (2010).
97. Mesia, K. et al. Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. part 1: A clinical phase IIA trial. Planta Med. 78, 211-218 (2011).
98. Xu, Y.-J. et al. Chromatographic profiling and identification of two new iridoid-indole alkaloids by UPLC-MS and HPLC-SPE-NMR analysis of an antimalarial extract from Nauclea pobeguinii. Phytochem. Lett. 5, 316-319 (2012).
99. Graz, B. et al. Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications. Trans. R. Soc. Trop. Med. Hyg. 104, 33-41 (2010).
100. Abdulla, S. & Sagara, I. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Malar. J. S1-S7 (2009).
101. Tshefu, A. K. et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375, 1457-1467 (2010).
102. Chandra, R. S. et al. Creative solutions to extraordinary challenges in clinical trials: methodology of a Phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa. Malar. J. 12, 1-8 (2013).
103. Keating, G. M. Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs 72, 937-961 (2012).
104. Schellenberg, D. et al. The safety and efficacy of sulfadoxine- pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 67, 17-23 (2002). (Pubitemid 35034314)
105. McGraw, E. A. & O'Neill, S. L. Beyond insecticides: new thinking on an ancient problem. Nature Rev. Microbiol. 11, 181-193 (2013).
106. Bian, G. et al. Wolbachia invades Anopheles stephensi populations and induces refractoriness to Plasmodium infection. Science 340, 748-751 (2013)
107. Agnandji, S. T. et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863 (2011).
108. D'Alessandro, U. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. New Engl. J. Med. 367, 2284-2295 (2012).
109. Riley, E. M. & Stewart, V. A. Immune mechanisms in malaria: new insights in vaccine development. Nature Med. 19, 168-178 (2013).
110. World Health Organization. Guidelines for the treatment of malaria. Second edition [online], http://www.who.int/malaria/publications/atoz/ 9789241547925/en/index.html (WHO, 2010).
111. Prudencio, M., Rodriguez, A. & Mota, M. M. The silent path to thousands of merozoites: the Plasmodium liver stage. Nature Rev. Microbiol. 4, 849-856 (2006). (Pubitemid 44593951)
112. Dixon, M. W., Thompson, J., Gardiner, D. L. & Trenholme, K. R. Sex in Plasmodium: a sign of commitment. Trends Parasitol. 24, 168-175 (2008).
113. Mantel, P. Y. et al. Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. Cell Host Microbe 13, 521-534 (2013).
114. Regev-Rudzki, N. et al. Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles. Cell 153, 1120-1133 (2013).
115. Aly, A. S., Vaughan, A. M. & Kappe, S. H. Malaria parasite development in the mosquito and infection of the mammalian host. Annu. Rev. Microbiol. 63, 195-221 (2009).
116. Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009).
117. Phyo, A. P. et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379, 1960-1966 (2012).
118. Cheeseman, I. H. et al. A major genome region underlying artemisinin resistance in malaria. Science 336, 79-82 (2012).
119. Miotto, O. et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genet. 45, 648-655 (2013).
120. Takala-Harrison, S. et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl Acad. Sci. USA 110, 240-245 (2013).
121. Mok, S. et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12, 391 (2011).
122. Mwakingwe, A. et al. Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites. J. Infect. Dis. 200, 1470-1478 (2009).
123. Schmidt, L. H. Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys. Antimicrob. Agents Chemother. 24, 615-652 (1983). (Pubitemid 14203859)
124. Russell, B. M. et al. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47, 170-173 (2003). (Pubitemid 36070360)
125. Jimenez-Diaz, M. B. et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2R?null mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53, 4533-4536 (2009).
126. Lelievre, J. et al. Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay. PLoS ONE 7, e35019 (2012).
127. Adjalley, S. H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108, E1214-E1223 (2011).
128. Miura, K. et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS ONE 8, e57909 (2013).
129. Churcher, T. S. et al. Measuring the blockade of malaria transmission-an analysis of the Standard Membrane Feeding Assay. Int. J. Parasitol. 42, 1037-1044 (2012).
130. Cassera, M. B. et al. Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal model. PLoS ONE 6, e26916 (2011).
131. Crockett, M. & Kain, K. C. Tafenoquine: a promising new antimalarial agent. Expert Opin. Investig. Drugs 16, 705-715 (2007). (Pubitemid 46723273)
132. Mesia, K. et al. Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 2: a clinical Phase IIB trial. Planta Med. 78, 853-860 (2012).
133. Bobenchick, A. M. et al. Plasmodium falciparum phosphoethanolamine methyltransferase is essential for malaria transmission. Proc. Natl Acad. Sci. USA http://dx.doi.org/10.1073/pnas.1313965110 (2013).
134. Hanson, K. K. et al. Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins. Proc. Natl Acad. Sci. USA 110, E2838-E2847 (2013).